6,976,810 Shares in Savara Inc. $SVRA Purchased by Nantahala Capital Management LLC

Nantahala Capital Management LLC acquired a new position in shares of Savara Inc. (NASDAQ:SVRA) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 6,976,810 shares of the company’s stock, valued at approximately $42,977,150. Savara comprises about 0.0% of Nantahala Capital Management LLC’s portfolio, making the stock its 8th biggest position. Nantahala Capital Management LLC owned about 3.40% of Savara as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Prudential Financial Inc. purchased a new position in shares of Savara in the 2nd quarter worth approximately $30,000. BNP Paribas Financial Markets increased its position in shares of Savara by 52.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock valued at $31,000 after purchasing an additional 4,626 shares during the last quarter. Brevan Howard Capital Management LP purchased a new stake in Savara during the 2nd quarter valued at $33,000. Russell Investments Group Ltd. raised its holdings in Savara by 930.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock valued at $37,000 after buying an additional 9,463 shares during the period. Finally, CIBC Bancorp USA Inc. bought a new stake in Savara in the third quarter worth $44,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

SVRA has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a research note on Friday, July 17th. Wall Street Zen lowered shares of Savara from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.14.

Savara Trading Down 4.2%

SVRA opened at $5.26 on Friday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 10.13 and a current ratio of 10.13. The stock’s 50 day moving average price is $5.70 and its 200-day moving average price is $5.48. Savara Inc. has a one year low of $3.19 and a one year high of $7.01. The stock has a market cap of $1.08 billion, a price-to-earnings ratio of -9.07 and a beta of 0.29.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). On average, equities analysts forecast that Savara Inc. will post -0.62 EPS for the current year.

Savara Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.